Open letter from the innovative pharmaceutical industry to G7 leaders

Ahead of the G7 Leaders’ Summit in Kananaskis from 15 to 17 2025, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda.

Pharmaceutical industry calls on G7 to prioritize innovation as strategic pillar for health, growth, and security

AMATA statement on the appointment of Dr Delese Mimi Darko as Director General of the African Medicines Agency

The founding members of the African Medicine Agency Treaty Alliance:  Amref Health Africa, the Association of African Universities North Africa Regional Office, the International Alliance of Patients’ Organizations, the International Federation of Pharmaceutical Manufacturers and Associations, the International Pharmaceutical Students’ Federation, NCD Alliance Kenya, PATH, Speak up Africa and the University of the Witwatersrand, welcome...

IFPMA congratulates Dr Delese Mimi Darko on being appointed new Director General of African Medicines Agency

On 4 June 2025, the African Medicines Agency (AMA) announced the appointment of Dr Delese Mimi Darko, Chief Executive of the Food and Drugs Authority in Ghana, as its next Director General. This marks a pivotal moment in making the AMA operational. By strengthening regulatory systems, the AMA will enhance the quality, safety, and efficacy...

WHA78 individual statement on antimicrobial resistance (AMR)

On 27 May 2025, IFPMA delievered a statement at the 78th session of the World Health Assembly on antimicrobial resistance.

WHA78 Fight the Fakes Alliance statement on substandard and falsified medical products

On 26 May 2025, the World Heart Federation delivered a statement on substandard and falsified medicines at the 78th session of the World Health Assembly. The World Heart Federation, supported by the Fight the Fakes Alliance, welcomes the independent evaluation of the Member State Mechanism on Substandard and Falsified Medical Products. Globally, countries waste an...

WHA78 AMATA statement on substandard and falsified medical products

On 26 May 2025, the International Alliance of Patients' Organizations, on behalf of the African Medicines Agency Treaty Alliance (AMATA), delivered a statement on substandard and falsified medical products at the 78th session of the World Health Assembly. As a member of AMATA, IFPMA supported this statement.

IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases

On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution...

WHA78 constituency statement on universal health coverage (UHC) and primary healthcare (PHC)

On 24 May 2025 at the 78th session of the World Health Assembly, the International Council of Nurses (ICN) delivered a statement on behalf of the World Health Professions Alliance (WHPA) on UHC and PHC.

WHA78 individual statement on non-communicable diseases

On 23 May 2025, IFPMA delivered a statement at the 78th session of the World Health Assembly on non-communicable diseases. IFPMA welcomes WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. We need to capture the political momentum before and during the UN High-Level Meeting in September to bend the...

WHA78 individual statement on the pandemic agreement

On 19 May 2025, IFPMA delivered a statement at the 78th session of the World Health Assembly on the pandemic agreement.

Statement at the Open Session of the Meeting of the 25th WHO Expert Committee on Selection and Use of Essential Medicines

On 5 May 2025, IFPMA delivered a statement at the open session of the meeting of the 25th WHO Expert Committee on Selection and Use of Essential Medicines.